Mr. Towarnicki joined Nucleonics as
President & CEO in 2003. At that time he was also named a member of
the board of directors. Prior to Nucleonics, Mr. Towarnicki served as
Chairman, President & CEO of Cell Pathways, Inc., an emerging
pharmaceutical company with two drugs in the clinic and one in-licensed
commercial product. Cell Pathways was acquired by OSI Pharmaceuticals
in June 2003. During his six-year tenure, Mr. Towarnicki led th...
more
Mr. Towarnicki joined Nucleonics as
President & CEO in 2003. At that time he was also named a member of
the board of directors. Prior to Nucleonics, Mr. Towarnicki served as
Chairman, President & CEO of Cell Pathways, Inc., an emerging
pharmaceutical company with two drugs in the clinic and one in-licensed
commercial product. Cell Pathways was acquired by OSI Pharmaceuticals
in June 2003. During his six-year tenure, Mr. Towarnicki led the
expansion of Cell Pathways from a virtual organization to a fully
integrated, NASDAQ listed, emerging pharmaceutical company. Prior to
joining Cell Pathways, Mr. Towarnicki led the development of Integra
LifeSciences Corporation. During his five years as President & COO,
he built Integra LifeSciences from a 12 person R&D organization
into a fully integrated medical device company trading on the NASDAQ.
Experience prior to Integra LifeSciences includes: General Manager of
Focus Technologies, a privately held esoteric disease reference
laboratory; VP of Development and Operations for Collagen Corporation;
Operations Manager for Pfizer Pharmaceuticals and, ten years of
increasing management responsibility in operations for Merck & Co.
In
2005, Mr. Towarnicki was named to the Biotechnology Industry
Organization (BIO) Emerging Companies Section Governing Body. Mr.
Towarnicki earned both a B.S. and M.S. in Biology from Villanova
University.
